- Home
- MGRM vs ADAP Comparison
MGRM vs ADAP Comparison
Compare MGRM & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRM
- ADAP
- Stock Information
- Founded
- MGRM 2016
- ADAP 2008
- Country
- MGRM United States
- ADAP United Kingdom
- Employees
- MGRM N/A
- ADAP N/A
- Industry
- MGRM Medical/Dental Instruments
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- MGRM Health Care
- ADAP Health Care
- Exchange
- MGRM Nasdaq
- ADAP Nasdaq
- Market Cap
- MGRM 79.9M
- ADAP 75.5M
- IPO Year
- MGRM N/A
- ADAP 2015
- Fundamental
- Price
- MGRM $2.41
- ADAP $0.29
- Analyst Decision
- MGRM Strong Buy
- ADAP Buy
- Analyst Count
- MGRM 1
- ADAP 6
- Target Price
- MGRM $5.40
- ADAP $1.52
- AVG Volume (30 Days)
- MGRM 69.5K
- ADAP 1.6M
- Earning Date
- MGRM 05-14-2025
- ADAP 05-13-2025
- Dividend Yield
- MGRM N/A
- ADAP N/A
- EPS Growth
- MGRM N/A
- ADAP N/A
- EPS
- MGRM N/A
- ADAP N/A
- Revenue
- MGRM N/A
- ADAP $179,639,000.00
- Revenue This Year
- MGRM N/A
- ADAP N/A
- Revenue Next Year
- MGRM N/A
- ADAP $52.49
- P/E Ratio
- MGRM N/A
- ADAP N/A
- Revenue Growth
- MGRM N/A
- ADAP 878.53
- 52 Week Low
- MGRM $1.92
- ADAP $0.20
- 52 Week High
- MGRM $4.21
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- MGRM 38.50
- ADAP 53.94
- Support Level
- MGRM $2.54
- ADAP $0.26
- Resistance Level
- MGRM $2.69
- ADAP $0.30
- Average True Range (ATR)
- MGRM 0.19
- ADAP 0.03
- MACD
- MGRM -0.02
- ADAP 0.00
- Stochastic Oscillator
- MGRM 13.79
- ADAP 58.12
About MGRM Monogram Orthopaedics Inc.
Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.